Dermata Therapeutics, Inc.
DRMA
$5.50
-$0.33-5.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.09% | 5.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.24% | -26.89% | |||
| Operating Income | 24.24% | 26.89% | |||
| Income Before Tax | 26.15% | 26.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.15% | 26.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.15% | 26.89% | |||
| EBIT | 24.24% | 26.89% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 62.92% | 51.26% | |||
| Normalized Basic EPS | 62.92% | 51.26% | |||
| EPS Diluted | 62.92% | 51.26% | |||
| Normalized Diluted EPS | 62.92% | 51.26% | |||
| Average Basic Shares Outstanding | 99.13% | 49.99% | |||
| Average Diluted Shares Outstanding | 99.13% | 49.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||